TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3893733

Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg at night)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29692272

Group type: EXPERIMENTAL
Intervention: Positive self-image
Number of subjects: 42

Group type: COMPARATOR
Intervention: Negative self-image
Number of subjects: 42
Study: 29773490

Group type: EXPERIMENTAL
Intervention: VSM arm (study website with vaccine information and social media components)
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: VI arm (website with vaccine information only)
Number of subjects: 1093

Group type: COMPARATOR
Intervention: VSM arm
Number of subjects: 1093

Group type: COMPARATOR
Intervention: VI arm
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Self-efficacy around vaccine decision making
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1093
Study: 26708921

Group type: EXPERIMENTAL
Intervention: Prediction model for ESD-induced perforation
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: Simplified weighted scoring system based on OR
Number of subjects: 2046
Study: 24415868

Group type: EXPERIMENTAL
Intervention: CIGB-230
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CIGB-230 (6 doses as late add-on)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no CIGB-230)
Number of subjects: 0
Study: 23111478

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy for 6 months
Number of subjects: 391

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 391
Study: 21029466

Group type: EXPERIMENTAL
Intervention: Continuous computer analysis of fetal monitoring signals with real-time alerts
Number of subjects: 8133

Group type: COMPARATOR
Intervention: Continuous CTG monitoring as previously performed
Number of subjects: 8133
Study: 18403419

Group type: EXPERIMENTAL
Intervention: Flexible GnRH antagonist protocol
Number of subjects: 270

Group type: COMPARATOR
Intervention: Flare-up GnRH agonist protocol
Number of subjects: 270
Study: 15816587

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 209

Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Epidural vein cannulation
Number of subjects: 209
Study: 12459133

Group type: EXPERIMENTAL
Intervention: Patient education (verbal and written information on generic vs brand-name drugs)
Number of subjects: 4620

Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 4620

Group type: EXPERIMENTAL
Intervention: Intervention practices (after intervention, before reference prices)
Number of subjects: 4620

Group type: EXPERIMENTAL
Intervention: Intervention practices (after application of reference prices)
Number of subjects: 4620

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 4620

Group type: COMPARATOR
Intervention: Control practices (after intervention, before reference prices)
Number of subjects: 4620

Group type: COMPARATOR
Intervention: Control practices (after application of reference prices)
Number of subjects: 4620
Study: 10385781

Group type: EXPERIMENTAL
Intervention: Second harmonic imaging
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fundamental imaging
Number of subjects: 40
Study: 8583018

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse, 18 mg per rinse
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine rinse, 20 mg per rinse
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control rinse (not specified)
Number of subjects: 24
Study: 2127178

Group type: EXPERIMENTAL
Intervention: Glibenclamid‐ratiopharm (treatment A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Reference preparation (treatment B)
Number of subjects: 80
Study: 6117901

Group type: EXPERIMENTAL
Intervention: Combination of prostacyclin (PGI2) and heparin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 24
Study: 30870257

Group type: EXPERIMENTAL
Intervention: Gadopiclenol (0.025, 0.05, 0.075, 0.1, 0.2, and 0.3 mmol/kg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Gadopiclenol (0.05, 0.075, 0.1, and 0.2 mmol/kg)
Number of subjects: 66
Study: 26023778

Group type: EXPERIMENTAL
Intervention: Two dose booster regimen of OCV (n = 184)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Single boosting dose of OCV
Number of subjects: 426

Group type: COMPARATOR
Intervention: Two dose primary series of OCV (n = 186)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Primary regimen in children
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Boosting regimen in children
Number of subjects: 426
Study: 24224448

Group type: EXPERIMENTAL
Intervention: Instant coffee with caffeine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Instant coffee without caffeine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Natural coffee with caffeine
Number of subjects: 17

Group type: COMPARATOR
Intervention: Natural coffee without caffeine
Number of subjects: 17
Study: 21640866

Group type: EXPERIMENTAL
Intervention: 1% casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no remineralization)
Number of subjects: 20
Study: 19540392

Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage colony-stimulating factor (GM-CSF) 3, 6, or 10 microg/kg per day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 16708532

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg slow release)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Zolpidem (6-hour prophylactic sleep)
Number of subjects: 8
Study: 15270791

Group type: EXPERIMENTAL
Intervention: Fasting Plasma Glucose (FPG)
Number of subjects: 6117

Group type: COMPARATOR
Intervention: Danish risk score
Number of subjects: 6117

Group type: COMPARATOR
Intervention: HbA1c
Number of subjects: 6117

Group type: EXPERIMENTAL
Intervention: Targeted screening using questionnaire followed by FPG
Number of subjects: 6117

Group type: COMPARATOR
Intervention: Population-based screening using FPG
Number of subjects: 6117

Group type: COMPARATOR
Intervention: Combination of questionnaire and FPG
Number of subjects: 6117
Study: 11453515

Group type: EXPERIMENTAL
Intervention: Experiential training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rational training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 9550641

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg o.d. (slow release formulation) for 1 week
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control measurements (no specific intervention mentioned)
Number of subjects: 10
Study: 8054323

Group type: EXPERIMENTAL
Intervention: Sugar beet (SB) fibre
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ispaghula (I) fibre
Number of subjects: 6

Group type: COMPARATOR
Intervention: Wheat bran (WB) fibre
Number of subjects: 6

Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 6
Study: 2903386

Group type: EXPERIMENTAL
Intervention: Oral co‐trimoxazole for 5 days
Number of subjects: 134

Group type: COMPARATOR
Intervention: Single intramuscular dose of fortified procaine penicillin and 5 days of oral ampicillin
Number of subjects: 134
Study: 7992070

Group type: EXPERIMENTAL
Intervention: Carboplatin 300 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 224
Study: 384325

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 30291011

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (systolic BP<120mmHg)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Less intensive blood pressure target (systolic BP<140mmHg)
Number of subjects: 529
Study: 28276086

Group type: EXPERIMENTAL
Intervention: Home-but not Alone mobile health application educational programme
Number of subjects: 250

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 250
Study: 27638058

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) with inspiratory resistance device set to 55% of maximum inspiratory effort (n=35)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo group with inspiratory resistance device set to 10% of maximum inspiratory effort (n=32)
Number of subjects: 67
Study: 24375223

Group type: COMPARATOR
Intervention: Low thoracic-epidural analgesia (TEA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Transversus-abdominis plane (TAP) block
Number of subjects: 44
Study: 22959906

Group type: EXPERIMENTAL
Intervention: LNG‐IUS
Number of subjects: 165

Group type: COMPARATOR
Intervention: MPA
Number of subjects: 165
Study: 19572180

Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser at 585 nm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser at 595 nm
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 15

Group type: COMPARATOR
Intervention: All groups (585 nm, 595 nm, and control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both 585 nm and 595 nm PDL treatments
Number of subjects: 15
Study: 17895284

Group type: EXPERIMENTAL
Intervention: Testosterone only
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Estradiol only
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Testosterone and estradiol
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: No testosterone and no estradiol
Number of subjects: 52
Study: 14535874

Group type: EXPERIMENTAL
Intervention: LC1 (fermented milk containing Lactobacillus johnsonii)
Number of subjects: 50
Study: 10895201

Group type: EXPERIMENTAL
Intervention: Doxorubicin (50 mg/m2 IV bolus) followed one hour later by Taxotere (60 mg/m2 IV infusion over 1 hour every 3 weeks for 6 cycles)
Number of subjects: 18
Study: 8831596

Group type: EXPERIMENTAL
Intervention: Oral ofloxacin
Number of subjects: 123

Group type: COMPARATOR
Intervention: Intravenous cefotaxime
Number of subjects: 123
Study: 1578593

Group type: EXPERIMENTAL
Intervention: Buprenorphine, 8 mg/d
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Methadone, 60 mg/d
Number of subjects: 162

Group type: COMPARATOR
Intervention: Methadone, 20 mg/d
Number of subjects: 162
Study: 3841130

Group type: EXPERIMENTAL
Intervention: Etretinate with a high fat meal
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Etretinate with whole milk
Number of subjects: 8

Group type: COMPARATOR
Intervention: Etretinate with a high carbohydrate meal
Number of subjects: 8

Group type: COMPARATOR
Intervention: Etretinate during a complete fast
Number of subjects: 8
Study: 30916161

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 52
Study: 28451529

Group type: EXPERIMENTAL
Intervention: Strengthened self-management program guidance (including seven modules: disease knowledge, breathing exercises, emotion management, home oxygen therapy, medicine intake technique, healthy life behaviors, action plans in deterioration stage)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional out-of-hospital continued nursing mode
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Strengthened self-management program guidance
Number of subjects: 86
Study: 25946480

Group type: EXPERIMENTAL
Intervention: Cell salvage (CS) transfusion
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Washed stored erythrocyte transfusion
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Unwashed stored erythrocyte transfusion
Number of subjects: 91
Study: 23046735

Group type: EXPERIMENTAL
Intervention: Altered taste perception
Number of subjects: 1745
Study: 21074809

Group type: EXPERIMENTAL
Intervention: Polaris ureteral stent
Number of subjects: 159

Group type: COMPARATOR
Intervention: InLay ureteral stent
Number of subjects: 159
Study: 19554005

Group type: EXPERIMENTAL
Intervention: Screening for inducible myocardial ischemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no screening)
Number of subjects: 0
Study: 17242627

Group type: EXPERIMENTAL
Intervention: Melatonin (3 or 6 mg depending on body weight)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 15473343

Group type: EXPERIMENTAL
Intervention: Blink Reflex (BR) elicited by stimulation of the supraorbital nerve
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 67
Study: 11736864

Group type: EXPERIMENTAL
Intervention: Six drug cocktail (caffeine 100 mg, mephenytoin 100 mg, debrisoquine 10 mg, chlorzoxazone 250 mg, diclofenac 25 mg, MDZ 5 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: MDZ alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Five drug cocktail (caffeine 100 mg, mephenytoin 100 mg, debrisoquine 10 mg, diclofenac 50 mg, without chlorzoxazone)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Six drug cocktail (as above with chlorzoxazone)
Number of subjects: 16
Study: 9431858

Group type: EXPERIMENTAL
Intervention: Lacidipine (2 mg once daily)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg once daily)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lacidipine plus Hydrochlorothiazide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8305770

Group type: EXPERIMENTAL
Intervention: Mylan's MTX tablets (15 mg administered as six 2.5-mg tablets)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lederle's MTX tablets (15 mg administered as six 2.5-mg tablets)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of Mylan's MTX to Lederle's MTX
Number of subjects: 22
Study: 3790405

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Anticholinergic drugs (Atropine and Glycopyrrolate)
Number of subjects: 5
Study: 31574025

Group type: EXPERIMENTAL
Intervention: Electrosclerotherapy (EST)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Bleomycin injection
Number of subjects: 5

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 5
Study: 30415082

Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention including reminders, care algorithms, training of a case manager, audit and feedback reports, and distribution of educational materials to health care providers.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine practice (control)
Number of subjects: 0
Study: 28733374

Group type: EXPERIMENTAL
Intervention: HbA1c measurement
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Estimated HbA1c (eA1C) calculation
Number of subjects: 387
Study: 25441015

Group type: EXPERIMENTAL
Intervention: Propranolol with memory reactivation (n=10)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Propranolol without memory reactivation (n=8)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Mifepristone with memory reactivation (n=13)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Mifepristone without reactivation (n=15)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Mifepristone plus d-cycloserine with reactivation (n=16)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Two placebos (n=15)
Number of subjects: 76
Study: 23530962

Group type: EXPERIMENTAL
Intervention: Full mouth periodontal treatment with an ultrasonic device and supragingival plaque control
Number of subjects: 15
Study: 21784145

Group type: EXPERIMENTAL
Intervention: n-3 supplementation (2.5 g/d, 2085 mg eicosapentaenoic acid and 348 mg docosahexanoic acid)
Number of subjects: 68
Study: 19322003

Group type: EXPERIMENTAL
Intervention: tamsulosin (group 1, 34 patients)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: terazosin (group 2, 35 patients)
Number of subjects: 107

Group type: COMPARATOR
Intervention: placebo (group 3, 38 patients)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: tamsulosin (group 1)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: terazosin (group 2)
Number of subjects: 107

Group type: COMPARATOR
Intervention: placebo (group 3)
Number of subjects: 107
Study: 16751617

Group type: EXPERIMENTAL
Intervention: Hypertonic-hyperoncotic solution (Poly-(O-2)-hydroxyethyl-starch 60.0 g, Na+ 1232 mmol/L, osmolality 2464 mOsmol/L)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hypertonic-hyperoncotic solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isotonic saline solution (0.9% sodium chloride)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 50
Study: 15310688

Group type: EXPERIMENTAL
Intervention: Nurse based outpatient management programme
Number of subjects: 208

Group type: COMPARATOR
Intervention: Conventional follow up
Number of subjects: 208
Study: 11220717

Group type: COMPARATOR
Intervention: Omeprazole therapy (40 or 60 mg daily as needed)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Antireflux surgery
Number of subjects: 310
Study: 9627297

Group type: EXPERIMENTAL
Intervention: Peritoneal macrophages of women with endometriosis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Macrophages of women with endometriosis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Peritoneal fluid (PF) of women with endometriosis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Western blot analysis
Number of subjects: 31
Study: 7931474

Group type: EXPERIMENTAL
Intervention: Oral vitamin A (100,000 IU/d) for 18 months
Number of subjects: 248

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 248
Study: 3229297

Group type: EXPERIMENTAL
Intervention: 5 mg/kg L-acetylcarnitine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 mg/kg L-acetylcarnitine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30 mg/kg L-acetylcarnitine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31041883

Group type: EXPERIMENTAL
Intervention: Intervention conditions in group randomized trials, specific details not provided.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions in group randomized trials, specific details not provided.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple-objective optimal designs, specific details not provided.
Number of subjects: 0
Study: 28944646

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - twelve 1-minute bouts at 95% estimated maximum workload (eWLmax) interspersed with 1-minute bouts at 40% eWLmax
Number of subjects: 22

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT) - 26 minutes at 55% estimated maximum workload (eWLmax)
Number of subjects: 22
Study: 26023808

Group type: EXPERIMENTAL
Intervention: Frontal-plane plyometric (FPP) training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sagittal-plane plyometric (SPP) training
Number of subjects: 14
Study: 26674200

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cathodal tDCS
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 11
Study: 23910199

Group type: EXPERIMENTAL
Intervention: Passive self-ligation brackets
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Active self-ligation brackets
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Damon Q brackets
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 96
Study: 21982758

Group type: EXPERIMENTAL
Intervention: 1 L/min O(2) via a demand system during sleep (n = 3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1 L/min O(2)/CO(2) mix (1.5% CO(2)) via a demand system during sleep (n = 4)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 125 mg acetazolamide 30 minutes before bedtime (n = 4)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (n = 4)
Number of subjects: 15
Study: 18781275

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 5 mg/kg over 24 h
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16861397

Group type: EXPERIMENTAL
Intervention: CD-ROM pain management program
Number of subjects: 37

Group type: COMPARATOR
Intervention: Wait-list group (control)
Number of subjects: 37
Study: 12854104

Group type: EXPERIMENTAL
Intervention: Dual therapy (standard peripheral intravenous nutrition with heparin and hydrocortisone plus topical GTN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monotherapy (standard peripheral intravenous nutrition with topical GTN only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple therapy (standard peripheral intravenous nutrition with heparin and hydrocortisone plus topical GTN)
Number of subjects: 0
Study: 10873990

Group type: EXPERIMENTAL
Intervention: Radiotherapy (10 Gy in five fractions over 5-7 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 39
Study: 8677204

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (obese, mildly hypertensive males)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: OSA patients
Number of subjects: 12
Study: 2398189

Group type: EXPERIMENTAL
Intervention: No. 08 Canal Finder System
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: No. 10 K‐file
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Pathfinder
Number of subjects: 270
Study: 6103299

Group type: EXPERIMENTAL
Intervention: Oral diethylcarbamazine citrate (DEC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topical diethylcarbamazine (DEC) lotion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (oral and topical DEC)
Number of subjects: 20
Study: 31820059

Group type: EXPERIMENTAL
Intervention: Topical insulin (30 International Units Insulin Regular in 30 ml of normal saline)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional dressing with normal saline (control group)
Number of subjects: 110
Study: 30237571

Group type: EXPERIMENTAL
Intervention: Maternal fish consumption 3 or more times per week during the last trimester of pregnancy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Maternal fish consumption 0-2 times per week during the last trimester of pregnancy
Number of subjects: 56
Study: 28146651

Group type: EXPERIMENTAL
Intervention: Centrifugal-flow LVAD (study device)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Axial-flow LVAD (control device)
Number of subjects: 446